Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers.

While the spread of values is not large enough to draw definitive conclusions, there appears to be a slight trend of smaller volume substituents correlating with more potent cellular activity.

also in 2,443 other papers